Merck Sharp & Dohme Corp. v. Hospira, Inc., No. 17-1115 (Fed. Cir. Oct. 26, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Merck Sharp & Dohme Corp. (“Merck”) appeals from the decision of the United States Dis trict Court for the District of Delaware concluding, after a bench trial , that claims 21 –34 (“the asserted claims”) of U.S. Patent 6,486,150 (“the ’150 patent”) are invalid under 35 U.S.C. § 103 (2006). See Merck Sharp & Dohme Corp. v. Hospira Inc., No. C V 14 -915-RGA, 2016 WL 5872620, at *21 (D. Del. July 10, 2016) ( Decision). Because the district court did not err in its conclusion of obviousness, we affirm.